T. Haigh

发表

Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205.

C. Münz, Michael A. Maurer, C. Cheong, 2013, Blood.

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

W. Chan, C. Bollard, M. Rowe, 2010, Blood.

CD8 T Cell Recognition of Endogenously Expressed Epstein-Barr Virus Nuclear Antigen 1

W. Hammerschmidt, A. Rickinson, N. Blake, 2004, The Journal of experimental medicine.

CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines

A. Rickinson, A. Leen, E. Houssaint, 2005, Journal of Virology.

A Role for Intercellular Antigen Transfer in the Recognition of EBV-Transformed B Cell Lines by EBV Nuclear Antigen-Specific CD4+ T Cells1

A. Rickinson, J. Brooks, G. Taylor, 2006, The Journal of Immunology.

Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma

A. Rickinson, N. Steven, S. Lee, 2004, Journal of Virology.

Jianmin after antigen targeting to DEC-205 transformed B cells − Robust T-cell stimulation by Epstein-Barr virus

C. Münz, Michael A. Maurer, C. Cheong, 2013 .

EBNA 1 Lessons from the EBV Nuclear Antigen T Cell Response : + Priming the Human CD 8 The Importance of Exogenous Antigen in Croom-Carter and

A. Rickinson, D. Croom-carter, T. Haigh, 2000 .

University of Birmingham CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV- transformed lymphoblastoid cell lines

E. Houssaint, A. Rickinson, S. Lee, 2012 .

CD 4 + T-cell responses to Epstein-Barr virus ( EBV ) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines

A. Rickinson, A. Leen, E. Houssaint, 2012 .

Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors

G. Taylor, James E Turner, T. Haigh, 2021, PLoS pathogens.

EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines1

E. Hui, A. Rickinson, G. Taylor, 2008, The Journal of Immunology.

LinesRecognition of EBV-Transformed B Cell Cytotoxic T Cell + LMP-Specific CD4 and 2 as Immunotherapeutic Targets: EBV Latent Membrane Proteins (LMPs) 1

E. Hui, A. Rickinson, H. Jia, 2008 .

Lines by EBV Nuclear Antigen-Specific CD4 the Recognition of EBV-Transformed B Cell A Role for Intercellular Antigen Transfer in

A. Rickinson, J. Brooks, G. Taylor, 2006 .

Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity

A. Rickinson, G. Taylor, T. Haigh, 2005, Journal of Virology.

Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display

A. Rickinson, G. Taylor, C. Leung, 2010, Proceedings of the National Academy of Sciences.

The role of tetraspanin CD63 in antigen presentation via MHC class II

A. Rickinson, E. Odintsova, F. Berditchevski, 2011, European journal of immunology.

Inhibition of Antigen Presentation by the Glycine/Alanine Repeat Domain Is Not Conserved in Simian Homologues of Epstein-Barr Virus Nuclear Antigen 1

R. Johnson, A. Rickinson, N. Blake, 1999, Journal of Virology.

Heterologous prime-boost vaccination protects from EBV antigen expressing lymphomas.

R. Khanna, C. Münz, G. Taylor, 2019, The Journal of clinical investigation.

Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.

R. Khanna, C. Münz, G. Taylor, 2019, The Journal of clinical investigation.

Epstein-Barr Virus Evades CD4+ T Cell Responses in Lytic Cycle through BZLF1-mediated Downregulation of CD74 and the Cooperation of vBcl-2

M. Rowe, A. Hislop, G. Taylor, 2011, PLoS pathogens.

Sierra M. Barone, P. Kearns, N. Khan, 2020, bioRxiv.

Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition.

G. Taylor, T. Haigh, H. Parry, 2022, Nature immunology.

Processing of a Multiple Membrane Spanning Epstein-Barr Virus Protein for Cd8+T Cell Recognition Reveals a Proteasome-Dependent, Transporter Associated with Antigen Processing–Independent Pathway

A. Rickinson, A. Leese, G. Taylor, 2001, The Journal of experimental medicine.

EBV-Specific CD4+ T Cell Clones Exhibit Vigorous Allogeneic Responses1

M. Bonneville, E. Houssaint, G. Taylor, 2006, The Journal of Immunology.

Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.

A. Fischer, Y. Hamel, M. Cavazzana‐Calvo, 2002, Human Gene Therapy.

Identification of a TAP-Independent, Immunoproteasome-Dependent CD8+ T-Cell Epitope in Epstein-Barr Virus Latent Membrane Protein 2

V. Cerundolo, A. Rickinson, A. Leese, 2003, Journal of Virology.

EBV-Specific CD 4 T Cell Clones Exhibit Vigorous Allogeneic Responses 1

M. Bonneville, E. Houssaint, G. Taylor, 2006 .

The Importance of Exogenous Antigen in Priming the Human CD8+ T Cell Response: Lessons from the EBV Nuclear Antigen EBNA11

A. Rickinson, D. Croom-carter, T. Haigh, 2000, The Journal of Immunology.

Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing.

Richard J. Jones, L. Young, N. Blake, 2003, Virology.

Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity

A. Sewell, P. Rizkallah, A. Greenshields-Watson, 2023, Cell reports.

High-Dimensional mass cytometry analysis reveals systemic immune perturbations in paediatric cancer influenced by age

Sierra M. Barone, P. Kearns, N. Khan, 2020 .

Heterologous prime-boost vaccination protects from EBV antigen expressing lymphomas.

R. Khanna, C. Münz, G. Taylor, 2019, The Journal of clinical investigation.

University of Birmingham Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas

R. Khanna, C. Münz, G. Taylor, 2019 .

The role of tetraspanin CD63 in antigen presentation via MHC class II

A. Rickinson, E. Odintsova, F. Berditchevski, 2011, European journal of immunology.